SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 22.46 |
| Enterprise Value ($M) | 3.10 |
| Book Value ($M) | 16.27 |
| Book Value / Share | 12.28 |
| Price / Book | 1.38 |
| NCAV ($M) | 16.27 |
| NCAV / Share | 12.28 |
| Price / NCAV | 1.38 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.98 |
| Return on Assets (ROA) | -0.27 |
| Return on Equity (ROE) | -0.52 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.82 |
| Current Ratio | 4.82 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 20.52 |
| Assets | 20.52 |
| Liabilities | 4.25 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lynx1 Capital Management LP | 2.80 | -99.62 | |
| 13G | ADAR1 Capital Management, LLC | 10.50 | ||
| 13G | Biotechnology Value Fund L P | 19.50 | -98.75 | |
| 13G/A | Checkpoint Capital L.P. | 0.00 | -100.00 | |
| 13G/A | Aquilo Capital Management, LLC | 1.10 | -80.16 | |
| 13G/A | Soleus Capital Master Fund, L.P. | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 157 | 3,299 | 4.76 | |
| 366 | 6,139 | 5.96 | |
| 9,032 | 29,373 | 30.75 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PCSA – Processa Pharmaceuticals, Inc. | PDSB – PDS Biotechnology Corporation |
| PHIO – Phio Pharmaceuticals Corp. | PLUR – Pluri Inc. |
| PMCB – PharmaCyte Biotech, Inc. |